For long-term storage, -80 C is preferred
Ozempic Continues Dominating Diabetes Care Ozempic remains one of the most recognized semaglutide products globally due to its strong effectiveness in reducing HbA1c levels and supporting weight loss among type 2 diabetes patients
These products are not intended for human consumption, veterinary use, self-administration, clinical use, treatment, diagnosis, prevention, cosmetic use, supplement use, body composition use or any form of personal use
For instance, In July 2024, the MHRA approved Semaglutide, a GLP-1 receptor agonist, to reduce the risk of major cardiovascular events in obese or overweight people, underscoring its expanding benefits beyond glycemic control In December 2023, Eli Lilly and Company launched Zepbound (tirzepatide), the first dual GIP/GLP-1 receptor agonist for chronic weight management in adults with obesity or other weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease Together, such developments are reshaping the role of GLP-1 analogues from single-purpose treatments to comprehensive metabolic health solutions